AIP
MCID: ACT029
MIFTS: 49

Acute Interstitial Pneumonia (AIP)

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Acute Interstitial Pneumonia

MalaCards integrated aliases for Acute Interstitial Pneumonia:

Name: Acute Interstitial Pneumonia 12 20 15 70
Hamman-Rich Syndrome 12 20 70
Acute Interstitial Pneumonitis 12 20
Idiopathic Pulmonary Fibrosis, Acute Fatal Form 12
Accelerated Interstitial Pneumonia 12
Idiopathic Pulmonary Fibrosis 70
Hamman-Rich Disease 12
Aip 12

Classifications:



Summaries for Acute Interstitial Pneumonia

GARD : 20 Acute interstitial pneumonia (AIP) is a rare and serious condition that affects the lungs. The signs and symptoms generally develop and progress rapidly. In the early stages of the condition, affected people may experience upper respiratory and/or viral-like symptoms such as cough, shortness of breath, and fever. This is followed by the rapid onset of respiratory failure and the need for mechanical ventilation in the majority of cases. The underlying cause of AIP is unknown. Most cases occur sporadically in people with no family history of the condition. There is, unfortunately, no proven treatment for AIP. Supportive care is generally recommended to address the signs and symptoms of the condition. Glucocorticoid therapy and other immunosuppressive therapies are often used; however, the benefits of these treatments remain unclear.

MalaCards based summary : Acute Interstitial Pneumonia, also known as hamman-rich syndrome, is related to idiopathic interstitial pneumonia and pneumonia, and has symptoms including dyspnea on exertion and dry cough. An important gene associated with Acute Interstitial Pneumonia is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Metabolism of proteins and Diseases of metabolism. The drugs Nintedanib and Analgesics, Non-Narcotic have been mentioned in the context of this disorder. Affiliated tissues include lung, pituitary and bone marrow, and related phenotypes are dyspnea and respiratory failure

Disease Ontology : 12 A idiopathic interstitial pneumonia which develops suddenly and is severe. Initially, the lung shows edema, hyaline membranes, and interstitial acute inflammation. Later, it develops loose organizing fibrosis, mostly within alveolar septa and type II pneumocyte hyperplasia. Fever, cough, and difficulty breathing develop over 1 to 2 weeks, typically progressing to acute respiratory failure.

Wikipedia : 73 Acute interstitial pneumonitis is a rare, severe lung disease that usually affects otherwise healthy... more...

Related Diseases for Acute Interstitial Pneumonia

Diseases related to Acute Interstitial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 462)
# Related Disease Score Top Affiliating Genes
1 idiopathic interstitial pneumonia 31.9 SFTPD SFTPC SFTPB SFTPA2
2 pneumonia 31.0 SFTPD SFTPC SFTPB MUC1 CRP
3 adult respiratory distress syndrome 30.1 SFTPD SFTPC SFTPB ABCA3
4 bronchopneumonia 30.0 CRP CD8A CD4
5 pulmonary fibrosis 30.0 SFTPD SFTPC SFTPA2 ELMOD2 ABCA3
6 mononeuropathy 29.8 CRP CD4
7 connective tissue disease 29.8 SFTPD MUC1 CRP CD8A CD4
8 pancytopenia 29.7 CRP CD8A CD4
9 nonspecific interstitial pneumonia 29.7 SFTPD SFTPC MUC1 IFIH1 ABCA3
10 pulmonary fibrosis, idiopathic 29.7 SPPL2C SFTPD SFTPC SFTPB SFTPA2 MUC1
11 autoimmune cholangitis 29.7 CD8A CD4
12 exanthem 29.6 IFIH1 CRP CD8A CD4
13 systemic scleroderma 29.6 SFTPD CRP CD8A CD4
14 respiratory failure 29.5 SFTPD SFTPC SFTPB CRP CD8A CD4
15 cryptogenic organizing pneumonia 29.5 SFTPD SFTPC SFTPA2 MUC1 CRP CD8A
16 interstitial lung disease 29.4 SFTPD SFTPC SFTPB SFTPA2 MUC1 IFIH1
17 celiac disease 1 29.4 IFIH1 CRP CD8A CD4
18 bacterial pneumonia 29.3 SFTPD SFTPB CRP CD8A CD4
19 lipid pneumonia 28.8 SFTPC SFTPB MUC1 CRP COPA ABCA3
20 lung disease 28.6 SFTPD SFTPC SFTPB SFTPA2 MUC1 IFIH1
21 porphyria, acute intermittent 11.6
22 acromegaly 11.4
23 pituitary adenoma 1, multiple types 11.4
24 autoimmune pancreatitis 11.4
25 adenoma 11.3
26 pituitary adenoma 11.3
27 pituitary adenoma, prolactin-secreting 11.3
28 aip familial isolated pituitary adenomas 11.2
29 hepatitis b 11.2
30 acth-secreting pituitary adenoma 11.2
31 hepatitis 11.1
32 familial isolated pituitary adenoma 11.1
33 gigantism 11.1
34 pituitary tumors 11.1
35 multiple endocrine neoplasia 11.1
36 growth hormone secreting pituitary adenoma 11.0
37 chester porphyria 11.0
38 pituitary apoplexy 11.0
39 porphyria 11.0
40 primary hyperparathyroidism 11.0
41 autoimmune pancreatitis type 1 11.0
42 acroleukopathy, symmetric 11.0
43 hormone producing pituitary cancer 10.9
44 tumor predisposition syndrome 10.9
45 cutaneous telangiectasia and cancer syndrome, familial 10.9
46 inherited cancer-predisposing syndrome 10.9
47 multiple endocrine neoplasia, type i 10.9
48 autoimmune pancreatitis type 2 10.9
49 carney complex variant 10.9
50 multiple endocrine neoplasia, type iv 10.9

Graphical network of the top 20 diseases related to Acute Interstitial Pneumonia:



Diseases related to Acute Interstitial Pneumonia

Symptoms & Phenotypes for Acute Interstitial Pneumonia

Human phenotypes related to Acute Interstitial Pneumonia:

31 (show all 32)
# Description HPO Frequency HPO Source Accession
1 dyspnea 31 hallmark (90%) HP:0002094
2 respiratory failure 31 hallmark (90%) HP:0002878
3 hypoxemia 31 hallmark (90%) HP:0012418
4 pulmonary infiltrates 31 hallmark (90%) HP:0002113
5 bronchiectasis 31 hallmark (90%) HP:0002110
6 ground-glass opacification on pulmonary hrct 31 hallmark (90%) HP:0025179
7 peribronchovascular interstitial thickening 31 hallmark (90%) HP:0025177
8 nodular pattern on pulmonary hrct 31 hallmark (90%) HP:0025392
9 reticulonodular pattern on pulmonary hrct 31 hallmark (90%) HP:0025393
10 interlobular septal thickening on pulmonary hrct 31 hallmark (90%) HP:0030879
11 hypertension 31 frequent (33%) HP:0000822
12 fatigue 31 frequent (33%) HP:0012378
13 fever 31 frequent (33%) HP:0001945
14 tachypnea 31 frequent (33%) HP:0002789
15 cyanosis 31 frequent (33%) HP:0000961
16 pleural effusion 31 frequent (33%) HP:0002202
17 nonproductive cough 31 frequent (33%) HP:0031246
18 crackles 31 frequent (33%) HP:0030830
19 decreased dlco 31 frequent (33%) HP:0045051
20 pulmonary fibrosis 31 occasional (7.5%) HP:0002206
21 arthralgia 31 occasional (7.5%) HP:0002829
22 myalgia 31 occasional (7.5%) HP:0003326
23 atelectasis 31 occasional (7.5%) HP:0100750
24 chest pain 31 occasional (7.5%) HP:0100749
25 lymphadenopathy 31 occasional (7.5%) HP:0002716
26 elevated c-reactive protein level 31 occasional (7.5%) HP:0011227
27 elevated erythrocyte sedimentation rate 31 occasional (7.5%) HP:0003565
28 pericardial effusion 31 occasional (7.5%) HP:0001698
29 peripheral edema 31 occasional (7.5%) HP:0012398
30 elevated serum creatinine 31 occasional (7.5%) HP:0003259
31 subpleural honeycombing 31 occasional (7.5%) HP:0031631
32 reduced hematocrit 31 occasional (7.5%) HP:0031851

UMLS symptoms related to Acute Interstitial Pneumonia:


dyspnea on exertion; dry cough

Drugs & Therapeutics for Acute Interstitial Pneumonia

Drugs for Acute Interstitial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nintedanib Approved Phase 4 656247-17-5 56843413
2 Analgesics, Non-Narcotic Phase 4
3 Anti-Inflammatory Agents, Non-Steroidal Phase 4
4
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
5
Pirfenidone Approved, Investigational Phase 3 53179-13-8 40632
6
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
9
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
10
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
11
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
12
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
13
Treprostinil Approved, Investigational Phase 3 81846-19-7 54786 6918140
14
Morphine Approved, Investigational Phase 3 57-27-2 5288826
15
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
16
Azathioprine Approved Phase 3 446-86-6 2265
17
Warfarin Approved Phase 3 81-81-2 6691 54678486
18
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
19
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
20
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
21
Sulfamethoxazole Approved Phase 3 723-46-6 5329
22
Losartan Approved Phase 2, Phase 3 114798-26-4 3961
23
Angiotensin II Approved, Investigational Phase 2, Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Anti-Inflammatory Agents Phase 3
27 Immunologic Factors Phase 3
28 Pharmaceutical Solutions Phase 3
29 Immunoglobulins Phase 3
30 Methylprednisolone Acetate Phase 3
31 Rho(D) Immune Globulin Phase 3
32 Immunoglobulins, Intravenous Phase 3
33 Antibodies Phase 3
34 gamma-Globulins Phase 3
35 glucocorticoids Phase 3
36 Protein Kinase Inhibitors Phase 2, Phase 3
37 Alkylating Agents Phase 3
38 Hormones Phase 3
39 Hormone Antagonists Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 Immunoglobulin G Phase 3
42 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
43 Antilymphocyte Serum Phase 3
44 Analgesics Phase 3
45 Narcotics Phase 3
46 Analgesics, Opioid Phase 3
47 Antimetabolites Phase 3
48 Anti-Bacterial Agents Phase 3
49 Anti-Infective Agents Phase 3
50 Interferon-gamma Phase 3

Interventional clinical trials:

(show top 50) (show all 361)
# Name Status NCT ID Phase Drugs
1 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
2 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
3 A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment. Completed NCT02788474 Phase 4 nintedanib;placebo
4 An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis Completed NCT02598193 Phase 4 Nintedanib;Pirfenidone
5 A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02579603 Phase 4 Nintedanib;Pirfenidone
6 Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study) Completed NCT02606877 Phase 4 nintedanib;pirfenidone
7 Digital Auscultation Tool - Development of an Innovative Approach - Using Modern Technologies - to Improve the Diagnosis of Rare Lung Diseases - Expanded Data Collection Idiopathic Pulmonary Fibrosis Completed NCT03503188 Phase 4
8 Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial Recruiting NCT03939520 Phase 4 pirfenidone and nintedanib;pirfenidone or nintedanib
9 Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis Terminated NCT01321996 Phase 4
10 Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL Terminated NCT03717012 Phase 4 Nintedanib
11 Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study Withdrawn NCT00625469 Phase 4 bosentan
12 Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study Withdrawn NCT00625079 Phase 4 sildenafil
13 A Randomized, Double-blinded, Placebo Controlled Study to Evaluate Clinical Efficacy and Safety of Pirfenidone for Skin Fibrosis in Systemic Sclerosis Unknown status NCT03068234 Phase 2, Phase 3 Pirfenidone;Placebo oral capsule;Steroids
14 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
15 Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00639496 Phase 3 n-acetylcysteine;placebo
16 Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443) Completed NCT00631475 Phase 3 Bosentan
17 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00600028 Phase 3 Thalidomide;Placebo
18 A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial) Completed NCT01366209 Phase 3 Pirfenidone;Placebo
19 Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123 Completed NCT02739165 Phase 3 ART-123;Placebo
20 An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00662038 Phase 3 pirfenidone
21 An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01619085 Phase 3 BIBF 1120
22 INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment Completed NCT02802345 Phase 3 Nintedanib;Placebo;Sildenafil
23 Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial Completed NCT02460588 Phase 3 Cyclophosphamide;Placebo;Corticosteroid (prednisolone)
24 A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
25 Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study. Completed NCT00391443 Phase 3 Bosentan;Placebo
26 A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287729 Phase 3 Pirfenidone;Placebo
27 A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287716 Phase 3 Pirfenidone;Placebo
28 A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
29 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
30 A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00047645 Phase 3 Interferon-gamma 1b
31 Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice Completed NCT03208933 Phase 3 Pirfenidone
32 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Completed NCT00517933 Phase 3 Sildenafil Citrate
33 A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01335464 Phase 3 placebo;BIBF 1120
34 A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01335477 Phase 3 placebo;BIBF 1120
35 A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) Completed NCT00105183 Phase 3
36 PAciFy Cough: A Multicentre, Double Blind, Placebo Controlled, Crossover Trial of Morphine Sulfate for the Treatment of PulmonAry Fibrosis Cough Recruiting NCT04429516 Phase 3 Morphine Sulfate;Placebo oral tablet
37 Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT04419558 Phase 3 Pamrevlumab;Placebo
38 Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Recruiting NCT04300920 Phase 3 N-acetyl cysteine;Placebo
39 A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT04594707 Phase 3 PRM-151
40 A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis Recruiting NCT04552899 Phase 3 PRM-151;Placebo
41 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT03955146 Phase 3 Pamrevlumab;Placebo
42 A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis Active, not recruiting NCT03733444 Phase 3 GLPG1690;Placebo
43 A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis Active, not recruiting NCT03711162 Phase 3 GLPG1690;Placebo
44 Determining the Effectiveness of Nebulized Morphine in Treating Dyspnea in Advanced Idiopathic Pulmonary Fibrosis Not yet recruiting NCT04497831 Phase 3 Morphine hydrochloride;Placebo
45 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Not yet recruiting NCT04708782 Phase 3 Placebo;Inhaled Treprostinil
46 ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF) Terminated NCT00768300 Phase 3 Ambrisentan;Placebo
47 A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone Terminated NCT00052039 Phase 3 interferon-gamma 1b;azathioprine
48 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension Terminated NCT00879229 Phase 3 Ambrisentan;Placebo
49 AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) Terminated NCT00957242 Phase 3 warfarin;placebo
50 Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis Terminated NCT02759120 Phase 3 Antimicrobial therapy: Co-trimoxazole or Doxycycline

Search NIH Clinical Center for Acute Interstitial Pneumonia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


nintedanib

Genetic Tests for Acute Interstitial Pneumonia

Anatomical Context for Acute Interstitial Pneumonia

MalaCards organs/tissues related to Acute Interstitial Pneumonia:

40
Lung, Pituitary, Bone Marrow, Bone, Liver, Thyroid, Skeletal Muscle

Publications for Acute Interstitial Pneumonia

Articles related to Acute Interstitial Pneumonia:

(show top 50) (show all 534)
# Title Authors PMID Year
1
Differential impacts of postoperative complications on patients' survival in completely resected non-small-cell lung cancer. 61
33687642 2021
2
Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5+ dermatomyositis. 61
33742662 2021
3
Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study. 61
32876818 2021
4
Reston virus causes severe respiratory disease in young domestic pigs. 61
33443221 2021
5
[Acute interstitial pneumonia in a patient treated with methotrexate: Late-onset with neutrophilia and eosinophilia in bronchoalveolar lavage fluid]. 61
33069501 2020
6
Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity. 61
33352104 2020
7
Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. 61
32949913 2020
8
COVID-19: a Great Mime or a Trigger Event of Autoimmune Manifestations? 61
33019935 2020
9
Transient Lymphopenia and Interstitial Pneumonia With Endotheliitis in SARS-CoV-2-Infected Macaques. 61
32745172 2020
10
Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison). 61
32663073 2020
11
The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. 61
32434133 2020
12
Acute interstitial pneumonia in foals: A severe, multifactorial syndrome with lung tissue recovery in surviving foals. 61
32986272 2020
13
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. 61
32332017 2020
14
Hamman-Rich Syndrome: A Diagnosis of Exclusion in the COVID-19 Pandemic. 61
32963907 2020
15
Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. 61
32277367 2020
16
Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome. 61
32447116 2020
17
Resecting a giant malignant lung tumor in a patient with unilateral acute interstitial pneumonitis. 61
32156474 2020
18
Outbreak of COVID-19 infection in children: fear and serenity. 61
32373997 2020
19
Lesions Observed Post Mortem in Post-hatchling Loggerhead Sea Turtles (Caretta caretta) from a Head Start Programme. 61
31955806 2020
20
Acute interstitial pneumonia triggered by strenuous exercise. 61
32382496 2020
21
Outbreak investigation of septicemic salmonellosis in calves. 61
32088691 2020
22
Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: Clinical and radiologic characteristics and risk factors. 61
31770246 2019
23
Time-course transcriptomic alterations reflect the pathophysiology of polyhexamethylene guanidine phosphate-induced lung injury in rats. 61
31971030 2019
24
Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. 61
31584861 2019
25
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction. 61
31172699 2019
26
Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. 61
31020569 2019
27
Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation. 61
30710119 2019
28
An Elusive Case of Acute Interstitial Pneumonia. 61
31333914 2019
29
Incidental tracheal bronchus in a case of Hamman-Rich syndrome. 61
31092498 2019
30
Up-regulation of THY1 attenuates interstitial pulmonary fibrosis and promotes lung fibroblast apoptosis during acute interstitial pneumonia by blockade of the WNT signaling pathway. 61
30829553 2019
31
Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases. 61
31839671 2019
32
Staphylococcus pseudintermedius septicemia in puppies after elective cesarean section: confirmed transmission via dam's milk. 61
30691457 2019
33
Pneumocystis jirovecii infection in patients with acute interstitial pneumonia. 61
29891174 2018
34
Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification. 61
30369660 2018
35
Clinical presentation and pathology of suspected vector transmitted African horse sickness in South African domestic dogs from 2006 to 2017. 61
29519857 2018
36
Extracorporeal Membrane Oxygenation for Refractory Severe Respiratory Failure in Acute Interstitial Pneumonia. 61
29323413 2018
37
Acute interstitial pneumonia as first presentation of anti-synthetase syndrome: an atypical case. 61
29644083 2018
38
Time course of polyhexamethyleneguanidine phosphate-induced lung inflammation and fibrosis in mice. 61
29476863 2018
39
Respiratory Mites ( Orthohalarachne diminuata) and β-hemolytic Streptococci-Associated Bronchopneumonia Outbreak in South American Fur Seal Pups ( Arctocephalus australis). 61
29369727 2018
40
Preliminary evidence that hydrostatic edema may contribute to the formation of diffuse alveolar damage in a Holstein calf model. 61
30555684 2018
41
Hamman-Rich syndrome. 61
29159034 2018
42
Acute respiratory failure due to diffuse parenchymal lung diseases in a respiratory intensive care unit of North India. 61
32476924 2018
43
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. 61
29293605 2018
44
[Efficacy and safety of transbronchial cryobiopsy in the etiologic diagnosis of diffuse lung disease]. 61
29275603 2017
45
[Clinical features of acute diffuse pulmonary exudative disorders]. 61
29275576 2017
46
Abruptio Placentae with Type II Respiratory Failure Secondary to Acute Interstitial Pneumonia Responsive to Steroids. 61
28969741 2017
47
[Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography]. 61
28872085 2017
48
A 45-Year-Old Woman with Acute Interstitial Pneumonia (Hamman-Rich Syndrome). 61
28868178 2017
49
Hamman-Rich syndrome: a forgotten entity. 61
28635201 2017
50
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). 61
28158568 2017

Variations for Acute Interstitial Pneumonia

Expression for Acute Interstitial Pneumonia

Search GEO for disease gene expression data for Acute Interstitial Pneumonia.

Pathways for Acute Interstitial Pneumonia

Pathways related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 SFTPD SFTPC SFTPB SFTPA2 MUC1 IFIH1
2
Show member pathways
11.43 SFTPD SFTPC SFTPB SFTPA2
3 11.23 SFTPC SFTPA2 ELMOD2
4
Show member pathways
10.65 SFTPD SFTPC SFTPB SFTPA2
5
Show member pathways
10.65 SFTPD SFTPC SFTPB SFTPA2 ABCA3
6 10.62 COPA CD4

GO Terms for Acute Interstitial Pneumonia

Cellular components related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.03 SFTPD SFTPC SFTPB SFTPA2 MUC1 CRP
2 extracellular space GO:0005615 9.92 SFTPD SFTPC SFTPB SFTPA2 MUC1 CRP
3 endoplasmic reticulum membrane GO:0005789 9.8 SPPL2C SFTPD SFTPC SFTPB SFTPA2 COPA
4 multivesicular body GO:0005771 9.54 SFTPD SFTPB SFTPA2
5 multivesicular body lumen GO:0097486 9.4 SFTPC SFTPB
6 lamellar body GO:0042599 9.33 SFTPC SFTPB SFTPA2
7 alveolar lamellar body GO:0097208 9.13 SFTPC SFTPB ABCA3
8 clathrin-coated endocytic vesicle GO:0045334 8.92 SFTPD SFTPC SFTPB SFTPA2

Biological processes related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.35 SFTPD SFTPC SFTPB SFTPA2 ABCA3
2 surfactant homeostasis GO:0043129 9.16 SFTPD ABCA3
3 respiratory gaseous exchange GO:0007585 8.92 SFTPD SFTPC SFTPB SFTPA2

Sources for Acute Interstitial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....